Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 47

recruiting
3 983
countries
28
conditions
2 109

10 385 trials match your criteria

Anaemia+1

Recruiting

A Phase 3 Study of Elritercept Versus Epoetin Alfa in ESA‑Naïve Adults with Lower‑Risk Myelodysplastic Syndrome Requiring Red Blood Cell Transfusions

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years

Interstitial lung disease+2

Recruiting

Carboplatin‑based drug combination for advanced non‑small cell lung cancer patients with interstitial lung disease

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years

Crohn's disease

Recruiting

One-Year Effectiveness Study of Guselkumab in Adults with Crohn’s Disease

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years

Back pain

Recruiting

Efficacy and tolerability of diclofenac potassium + thiocolchicoside versus diclofenac potassium in patients with acute severe low back pain

Registered drug
Countries:CyprusCyprus
  • Participants:18–64 years · 65+ years
  • Substances:Diclofenac potassium

B-cell type acute leukaemia

Recruiting

Optimizing fludarabine phosphate exposure to improve event‑free survival in children and young adults with B‑cell acute lymphoblastic leukemia receiving CAR‑T therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years

Neoplasm malignant+1

Recruiting

Anti‑PD1 Therapy with pembrolizumab and cemiplimab in first‑line advanced non‑small cell lung cancer patients with high PD‑L1 expression

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years

Neoplasm malignant+1

Recruiting

A Phase I/II Study of GVV858 Alone or in Drug Combination for Patients with Advanced Hormone Receptor‑Positive, HER2‑Negative Breast Cancer

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years

Diffuse large B-cell lymphoma refractory+1

Recruiting

Glofitamab plus drug combination for relapsed/refractory large B‑cell lymphoma in high‑risk second‑line patients eligible for CAR‑T therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lisocabtagene Maraleucel

Hypochondroplasia

Recruiting

Long‑Term Safety and Efficacy of Infigratinib in Children with Hypochondroplasia

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:0–17 years

Acute myeloid leukaemia refractory+2

Recruiting

Phase 1/2 Study of LB-208 in Adults with Relapsed or Refractory Acute Myeloid Leukaemia and High‑Risk Myelodysplastic Syndrome

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years

Rett syndrome

Recruiting

A Phase 3 Study of Fenfluramine Hydrochloride for Safety and Efficacy in Patients with Rett Syndrome

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years

Small cell lung cancer metastatic

Recruiting

Phase II Study of Intravenous Tarlatamab for Patients with Asymptomatic Brain Metastases from Small Cell Lung Cancer

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.